Actinic Keratosis Treatment Companies

Biofrontera AG commercially launches AMELUZ in Finland: This product approval expands Biofrontera's reach in Europe and offers an alternative to traditional photodynamic therapy with its BF-RhodoLED lamp

Almirall receives FDA approval for Klisyri (tirbanibulin): This new topical cream offers a once-daily application option for AK treatment, potentially improving patient compliance.

Cipher Pharmaceuticals Inc. expands distribution of Zyclara® (imiquimod): This established topical cream sees continued market penetration, solidifying its position in the AK treatment landscape.

Sun Pharmaceutical Industries Ltd. acquires Taro Pharmaceuticals Holdings Inc.: This acquisition consolidates Sun Pharma's position in the dermatology market, potentially impacting AK treatment offerings.

Valeant Pharmaceuticals announces positive Phase 3 results for Duavlir (alimetinib/ingenol mebutate): This investigational topical gel demonstrates promising efficacy and safety in AK treatment, potentially entering the market soon.

• Stanford Chemicals (US)


• Alma Lasers (Israel), 


• 3M (US),


• Sun Pharmaceutical Industries Ltd. (India),


• Galderma S.A (Switzerland),


• Leo Pharma (Denmark),


• Valeant Pharmaceuticals (US),


• BioLineRx (Israel),


• Cipher Pharmaceuticals Inc (Canada),


• Biofrontera AG (Germany)